Cingulate Inc. (CING)
Develops new ADHD and anxiety medications using a specialized drug delivery platform.
$4.53+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-11.2%
The outlook
CING is trading near the lower end of its 52-week range and below both its 50- and 200-day moving averages, reflecting a bearish technical backdrop. Analyst coverage leans bullish on valuation, with an average price target implying significant upside from current levels, though the stock's recent weakness suggests caution. The overall sentiment score reflects mixed signals between technical weakness and optimistic longer-term targets.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range16% of the way from its 52-week low to high
Price targetAvg target +408% vs current price
Analyst price target
~12-month · 5 analysts$23.00average target+407.7% vs now
Now $4.53
Low $8.00High $52.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$61.0M
52-wk high
$11.89
52-wk low
$3.16
50-day avg
$4.74
200-day avg
$5.08
Trailing P/E
—